Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Inclusion Criteria: * Fasting, stable LDL-C ≥ 160 mg/dL * Fasting, stable triglyceride \< 400 mg/dL * BMI between 22 and 35 kg/m2, inclusive * Females must be of non-child bearing potential * Males of reproductive potential must agree to practice effective contraception throughout the study and for 3 months following infusion Exclusion Criteria: * Clinically significant endocrine, hematologic, renal, hepatic, pulmonary, uncontrolled psychiatric, or neurologic disease * Cancer within 5 years prior to screening * History of congestive heart failure or chronic heart failure * Uncontrolled cardiac arrhythmias * History of coronary heart disease * Clinically significant abnormal baseline ECG * History of additional risk factors for torsades de pointes * Hepatitis B, C, or HIV positive * Current diagnosis or known history of liver disease * A marked baseline prolongation of QT/QTc interval * Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained muscle pain, or a creatine phosphokinase (CPK) \>3 x upper limit of normal (ULN) at screening * Alanine aminotransferase, AST, GGT, or total bilirubin \>2 x ULN at screening * Serum creatinine \> 1.5 mg/dL * Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on 2 occasions during screening * Concomitant use of medications that prolongs the QT/QTc interval * Treatment with lipid lowering therapy within 30 days prior to screening * Use of investigational drug within 3 months prior to screening